FDA Reproductive Cmte. Membership Reflects “Broken Process” – Crawford
FDA's difficulty in staffing the Reproductive Health Drugs Advisory Committee is a result of a "broken process," Acting Commissioner Lester Crawford told a Women in Government Relations luncheon in Washington, D.C. Oct. 11
More from Archive
More from Pink Sheet
Pharma firms are being encouraged to respond to a European Commission consultation on planned updates to its good manufacturing practice standards which reflect the “rapid advancement” of modern technologies, like AI and digital systems, in drug manufacturing.
China has announced a raft of new measures to encourage innovative drug development across the product life cycle, including using insurance data to differentiate new therapies and applying commercial insurance to selected novel products.
Lawmakers should address FDA staff upheaval and help the agency “get back on track,” former agency Chief of Staff Elizabeth Jungman said, while CBER Director Vinay Prasad told staff he is asking ex-colleagues to return to the agency.